Five‐year clinical follow‐up of a randomized comparison of a polymer‐free sirolimus‐eluting stent versus a polymer‐based paclitaxel‐eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 83, Iss. 3, 2014-02 ,pp. : 418-424

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stent Thrombosis with Biodegradable Polymer Drug-Eluting Stents versus Durable Polymer Sirolimus-Eluting Stents: An Update Meta-Analysis

By  

Cardiology, Vol. 130, Iss. 2, 2015-01 ,pp. : 96-105

Karger

Access to resources Recommend Favorite

A 10‐month angiographic and 4‐year clinical outcome of everolimus‐eluting versus sirolimus‐eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 7, 2015-12 ,pp. : 1161-1167

John Wiley & Sons Inc

Access to resources Recommend Favorite

First‐in‐man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus‐eluting stent in the treatment of patients with de novo coronary lesions: Clinical, Angiographic, and OCT outcomes of CREDIT‐1

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. S1, 2015-03 ,pp. : 744-751

John Wiley & Sons Inc

Access to resources Recommend Favorite

The real world experience of the biodegradable polymer‐coated sirolimus‐eluting coronary stent system

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 88, Iss. 3, 2016-09 ,pp. : E93-E98

John Wiley & Sons Inc

Access to resources Recommend Favorite